Showing results (21-30 of 383) with videos related to

Sort By:
Pageof 39
American Journal of Clinical Pathology|June 14, 2014
Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomasBeth Z Clark, Surabhi Beriwal, David J Dabbs, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 6, 2009
Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFRRohit Bhargava, Sushil Beriwal, Joan M Striebel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 5, 2008
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) casesMamatha Chivukula, Rohit Bhargava, Adam Brufsky, et al.
American Journal of Clinical Pathology|December 18, 2013
Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ casesFaye F Gao, David J Dabbs, Kristine L Cooper, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 3, 2020
Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK™) index for breast cancer prognosisSwikrity Upadhyay Baskota, David J Dabbs, Beth Z Clark, et al.
American Journal of Clinical Pathology|February 8, 2017
Male Breast CancerKate M Serdy, José Pablo Leone, David J Dabbs, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 13, 2012
Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 casesBeth Z Clark, David J Dabbs, Kristine L Cooper, et al.
American Journal of Clinical Pathology|June 21, 2011
Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristicsJing Yu, David J Dabbs, Yongli Shuai, et al.
American Journal of Clinical Pathology|February 21, 2008
The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient managementJoan M Striebel, Rohit Bhargava, Craig Horbinski, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 25, 2008
Histopathologic variables predict Oncotype DX recurrence scoreMelina B Flanagan, David J Dabbs, Adam M Brufsky, et al.
Pageof 39